查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2030080

細胞檢測市場－全球產業規模、佔有率、趨勢、機會和預測：按產品/服務、應用、最終用戶、地區和競爭對手分類，2021-2031年

Cell Based Assays Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Products & Services, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球細胞檢測市場預計將從 2025 年的 174.6 億美元成長到 2031 年的 289.5 億美元，複合年成長率為 8.79%。

這些檢測方法利用實驗室環境中的活細胞來研究生物功能、評估細胞對外部因素的反應，並篩檢有前景的候選藥物。市場擴張的主要驅動力是生物技術和製藥領域研發投入的增加、對個人化醫療和生物製藥日益成長的需求，以及高通量篩檢技術的不斷進步。這些因素凸顯了基於細胞的檢測方法在現代毒理學、藥物發現和治療方法進展中發揮的關鍵作用。

市場概覽
預測期 2027-2031
市場規模：2025年 174.6億美元
市場規模：2031年 289.5億美元
複合年成長率：2026-2031年 8.79%
成長最快的細分市場 藥物發現與開發
最大的市場 北美洲

儘管取得了這些積極進展，但與檢測方法開發、專用設備以及各種細胞株的持續維護相關的巨額成本仍然是市場成長的主要障礙。這些經濟壁壘可能會限制技術的普及應用，尤其是在小規模的研究機構。然而，整個生物科學領域仍在持續吸引大量資本。根據生物技術創新組織 (BIO) 2025 年 12 月的報告顯示，美國生物科學產業的創業投資從 2023 年的 233 億美元增加到 2024 年的 260 億美元。這筆強勁的資金籌措支持著對細胞檢測方法持續應用至關重要的基礎研究和開發工作。

市場促進因素

藥物發現和開發領域日益成長的需求是全球細胞分析市場的主要驅動力，也因此更凸顯了對可靠高效篩檢工具的需求。生物製藥公司致力於解決尚未解決的醫學難題，而這些分析方法對於識別潛在療法、評估其療效以及闡明其作用機制至關重要。透過使研究人員能夠在受控條件下模擬複雜的生物系統和疾病狀態，這些調查方法能夠加速藥物發現的早期階段。 BioSpace在2026年3月發布的報告也印證了這一趨勢：16家大型製藥企業在2025年總合投入1591億美元用於研發，這確保了對先進細胞篩檢技術的持續需求。

細胞檢測技術的突破性進展正推動著另一項重大進步，其應用範圍不斷擴大，整體效能顯著提升。單細胞分析平台、3D細胞培養和高通量篩檢等創新技術能夠提供更符合生理法則且更具預測性的結果，使其成為傳統方法的理想替代方案。人工智慧 (AI) 和自動化技術的整合進一步最佳化了資料解讀和檢測執行，從而實現了更具擴充性和效率的流程。 2025年10月發布的《2025年生物製藥指數》反映了這項技術變革，指出85%的生物製藥公司高階主管計畫投資於人工智慧驅動的研發和臨床試驗。這一發展勢頭也得到了更廣泛的經濟趨勢的支持。正如BioBridge Global在2025年3月預測的那樣，全球生物技術投資預計將在2025年達到5,460億美元，這充分證明了對細胞檢測創新生態系統的強勁資金支持。

市場挑戰

專用設備、檢測方法開發以及多種細胞株的持續維護等相關成本高昂，直接阻礙了全球細胞檢測市場的擴張。這些巨額支出限制了其廣泛應用，尤其是在學術機構和小規模研究機構中，這些機構可能缺乏啟動和長期運作所需的資金。購置尖端設備、建立專有檢測方案以及維護豐富的細胞株庫都是耗資巨大的工作，對市場准入和廣泛應用構成了重大障礙。

這種經濟壓力在生命科學產業普遍存在。例如，根據歐洲製藥工業協會聯合會（EFPIA）的報告，光是2024年，歐洲製藥業在研發方面的投資就超過550億歐元。如此巨額的支出凸顯了藥物發現和開發的高度資本密集特性，而藥物發現和開發又高度依賴基於細胞的檢測方法。持續的大量資金需求表明，檢測組件固有的高成本不斷給研發預算帶來壓力，從而延緩了新檢測技術的廣泛應用，並限制了關鍵創新資源的取得。

市場趨勢

全球細胞分析市場深受即時、無標定檢測系統日益普及的影響，這些系統能夠以連續、非侵入性的方式觀察細胞活動。電阻檢測和表面等離子體共振等技術無需標記物，從而避免了對細胞生理功能的干擾，因此能夠產生更可靠、更準確的生物學數據。藥物研發流程中對高品質數據和簡化檢測程序的需求推動了這些技術的廣泛應用。 Biocompare 於 2026 年 2 月 16 日發布的報告《SLAS2026 產品公告、新聞和趨勢》印證了這一趨勢，報告指出 Carterra 的新型 Vega 高通量表面等離子體共振系統每天可評估超過 20,000 個小分子相互作用。此類創新使科學家能夠透過即時觀察分子間相互作用快速識別有前景的治療化合物，從而加速藥物研發的早期階段。

多重檢測和高內涵篩檢調查方法的興起是該產業另一個重要趨勢。這些技術使研究人員能夠在單次實驗中同時評估多種生物標記和細胞參數，從而從每個樣本中獲得更豐富、更全面的資料集。因此，該領域的研究正從基本的單終點測量轉向對複雜疾病機制和細胞表現型的深入理解。特別是高內涵篩檢，它利用先進的成像技術和軟體對各種細胞成分進行定量分析。能夠分析40多種顏色的流式細胞技術系統的常規應用，清楚地展現了多重檢測技術的進步，促進了詳細的免疫分析和複雜細胞特性的分析。這種能力顯著提高了基於細胞的檢測的數據輸出和操作效率，從而能夠進行精準的毒性評估和藥物分析，這對於個人化醫療至關重要。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球細胞檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品/服務分類（試劑、檢測試劑盒、微孔盤、探針/標籤、細胞株、其他）
    • 按應用領域（臨床研究、藥物發現/開發、其他）
    • 按最終用戶（生物技術和製藥公司、學術和研究機構、受託研究機構）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美細胞檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲細胞檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區細胞檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲細胞檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美細胞檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球細胞偵測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Corning Inc.
  • Bio-Rad Laboratories Inc.
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Lonza Group AG
  • Promega Corporation
  • F. Hoffmann-La Roche AG
  • Merck KGaA
  • Charles River Laboratories International Inc.
  • Menarini Silicon Biosystems Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 14420

The Global Cell Based Assays Market is projected to grow from USD 17.46 Billion in 2025 to USD 28.95 Billion by 2031 at a 8.79% CAGR. These assays utilize living cells in laboratory settings to study biological functions, evaluate cellular reactions to external factors, and screen potential drug candidates. The market's expansion is primarily fueled by rising research and development investments within the biotechnology and pharmaceutical sectors, a growing demand for personalized medicine and biologics, and continuous improvements in high-throughput screening technologies. These elements highlight the crucial role of cell-based assays in modern toxicology, drug discovery, and therapeutic advancement.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 17.46 Billion
Market Size 2031USD 28.95 Billion
CAGR 2026-20318.79%
Fastest Growing SegmentDrug Discovery & Development
Largest MarketNorth America

Even with this positive trajectory, the substantial costs linked to assay formulation, specialized equipment, and the ongoing preservation of diverse cell lines pose a major obstacle to market growth. Such financial barriers can restrict adoption, especially for smaller research institutions. However, the wider bioscience sector continues to attract significant capital; as reported by the Biotechnology Innovation Organization (BIO) in December 2025, venture capital investment in the U.S. bioscience industry reached $26 billion in 2024, an increase from $23.3 billion in 2023. This robust funding sustains the foundational research and development essential for the continued utilization of cell-based assays.

Market Driver

The escalating requirements of drug discovery and development act as a major catalyst for the Global Cell Based Assays Market, amplifying the need for dependable and efficient screening tools. As biopharmaceutical firms strive to address unmet medical conditions, these assays have become essential for pinpointing potential therapeutics, measuring their efficacy, and deciphering their functional mechanisms. By allowing researchers to simulate complex biological systems and disease states under controlled conditions, these methodologies expedite the early stages of drug creation. Highlighting this trend, BioSpace reported in March 2026 that the 16 leading pharmaceutical corporations collectively spent $159.1 billion on research and development in 2025, ensuring a sustained demand for advanced cell-based screening technologies.

Technological breakthroughs in cell-based assays serve as another critical driver by broadening their applications and improving their overall capabilities. Innovations such as single-cell analysis platforms, 3D cell cultures, and high-throughput screening deliver more physiologically accurate and predictive results, making them highly preferable to conventional approaches. Integrating artificial intelligence and automation further refines data interpretation and assay execution, leading to more scalable and efficient processes. Reflecting this technological shift, The 2025 Biopharma Index noted in October 2025 that 85% of biopharma executives intended to invest in AI-driven research and development and clinical trials. This momentum is supported by larger economic patterns; as projected by BioBridge Global in March 2025, global biotech investment was expected to reach $546 billion in 2025, demonstrating robust financial backing for the cell-based assay innovation ecosystem.

Market Challenge

The significant expenses associated with specialized equipment, assay development, and the continuous maintenance of varied cell lines present a direct hurdle to the expansion of the Global Cell Based Assays Market. These steep financial outlays limit widespread utilization, particularly among academic institutions and smaller research entities that may lack the substantial capital necessary for upfront setup and long-term operation. Procuring cutting-edge machinery, establishing proprietary assay protocols, and sustaining a robust inventory of distinct cell lines are costly endeavors that create formidable barriers to market entry and broader adoption.

This economic pressure is widely recognized across the broader life sciences industry. As an illustration, the European Federation of Pharmaceutical Industries and Associations (EFPIA) reported that the European pharmaceutical sector invested more than €55 billion in research and development in 2024 alone. Such massive expenditure emphasizes the heavily capital-intensive nature of drug discovery and development, a field that heavily relies on cell-based assays. The constant need for significant financial backing demonstrates how the naturally high costs of assay components continually stretch research budgets, ultimately slowing the widespread integration of novel testing technologies and restricting access to vital innovative resources.

Market Trends

The Global Cell Based Assays Market is profoundly influenced by the expansion of real-time and label-free detection systems, which are becoming increasingly popular for delivering continuous, non-invasive observations of cellular activities. Techniques such as impedance-based detection and surface plasmon resonance bypass the need for labels that might interfere with cell physiology, thereby generating more authentic and precise biological data. Their rising adoption is fueled by the need for superior data quality and simplified testing procedures in drug development workflows. Highlighting this trend, a February 16, 2026, Biocompare report on 'Product Launches, News, and Trends from SLAS2026' revealed that Carterra's new Vega high-throughput surface plasmon resonance device can evaluate over 20,000 small-molecule interactions daily. Such innovations allow scientists to swiftly pinpoint promising therapeutic compounds by observing molecular interactions in real time, expediting the initial stages of drug formulation.

The rise of multiplexed and high-content screening methodologies marks another influential industry trend. These techniques permit researchers to evaluate numerous biomarkers and cellular parameters concurrently within a single experiment, producing a richer and more comprehensive dataset from each sample. Consequently, the field is moving away from basic single-endpoint measurements toward a deeper comprehension of intricate disease mechanisms and cellular phenotypes. High-content screening specifically utilizes advanced imaging and software to quantitatively analyze diverse cellular components. The growing sophistication of multiplexed testing is highlighted by the routine availability of flow cytometry systems capable of analyzing over 40 distinct colors, facilitating detailed immune profiling and complex cell characterization. This capability drastically improves the data output and operational efficiency of cell-based assays, enabling the precise toxicity evaluations and drug profiling essential for personalized medicine.

Key Market Players

  • Corning Inc.
  • Bio-Rad Laboratories Inc.
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Lonza Group AG
  • Promega Corporation
  • F. Hoffmann-La Roche AG
  • Merck KGaA
  • Charles River Laboratories International Inc.
  • Menarini Silicon Biosystems Inc.

Report Scope

In this report, the Global Cell Based Assays Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Based Assays Market, By Products & Services

  • Reagents
  • Assay Kits
  • Microplates
  • Probes & Labels
  • Cell Lines
  • Others

Cell Based Assays Market, By Application

  • Clinical Research
  • Drug Discovery & Development
  • Others

Cell Based Assays Market, By End User

  • Biotechnology & Pharmaceutical Companies
  • Academic & Research Institutions
  • Contract Research Organizations

Cell Based Assays Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Based Assays Market.

Available Customizations:

Global Cell Based Assays Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Based Assays Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Products & Services (Reagents, Assay Kits, Microplates, Probes & Labels, Cell Lines, Others)
    • 5.2.2. By Application (Clinical Research, Drug Discovery & Development, Others)
    • 5.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Contract Research Organizations)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Cell Based Assays Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Products & Services
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cell Based Assays Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Products & Services
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Cell Based Assays Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Products & Services
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Cell Based Assays Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Products & Services
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Cell Based Assays Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Products & Services
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cell Based Assays Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Products & Services
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. France Cell Based Assays Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Products & Services
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Cell Based Assays Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Products & Services
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Cell Based Assays Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Products & Services
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Cell Based Assays Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Products & Services
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia Pacific Cell Based Assays Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Products & Services
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cell Based Assays Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Products & Services
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Cell Based Assays Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Products & Services
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Cell Based Assays Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Products & Services
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Cell Based Assays Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Products & Services
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Cell Based Assays Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Products & Services
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. Middle East & Africa Cell Based Assays Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Products & Services
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cell Based Assays Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Products & Services
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Cell Based Assays Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Products & Services
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Cell Based Assays Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Products & Services
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. South America Cell Based Assays Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Products & Services
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cell Based Assays Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Products & Services
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Cell Based Assays Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Products & Services
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Cell Based Assays Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Products & Services
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cell Based Assays Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Corning Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bio-Rad Laboratories Inc.
  • 15.3. Thermo Fisher Scientific Inc.
  • 15.4. Danaher Corporation
  • 15.5. Lonza Group AG
  • 15.6. Promega Corporation
  • 15.7. F. Hoffmann-La Roche AG
  • 15.8. Merck KGaA
  • 15.9. Charles River Laboratories International Inc.
  • 15.10. Menarini Silicon Biosystems Inc.

16. Strategic Recommendations

17. About Us & Disclaimer